DE69032209D1 - In menschlichen kolorektalkarzinomen fehlendes gen - Google Patents

In menschlichen kolorektalkarzinomen fehlendes gen

Info

Publication number
DE69032209D1
DE69032209D1 DE69032209T DE69032209T DE69032209D1 DE 69032209 D1 DE69032209 D1 DE 69032209D1 DE 69032209 T DE69032209 T DE 69032209T DE 69032209 T DE69032209 T DE 69032209T DE 69032209 D1 DE69032209 D1 DE 69032209D1
Authority
DE
Germany
Prior art keywords
dcc
human
human colorectal
colorectal carcinomas
gene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69032209T
Other languages
English (en)
Other versions
DE69032209T2 (de
Inventor
Bert Vogelstein
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Johns Hopkins University
Original Assignee
Johns Hopkins University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Johns Hopkins University filed Critical Johns Hopkins University
Application granted granted Critical
Publication of DE69032209D1 publication Critical patent/DE69032209D1/de
Publication of DE69032209T2 publication Critical patent/DE69032209T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6827—Hybridisation assays for detection of mutation or polymorphism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6827—Hybridisation assays for detection of mutation or polymorphism
    • C12Q1/683—Hybridisation assays for detection of mutation or polymorphism involving restriction enzymes, e.g. restriction fragment length polymorphism [RFLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57419—Specifically defined cancers of colon
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/811—Test for named disease, body condition or organ function
    • Y10S436/813—Cancer
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/14—Heterocyclic carbon compound [i.e., O, S, N, Se, Te, as only ring hetero atom]
    • Y10T436/142222—Hetero-O [e.g., ascorbic acid, etc.]
    • Y10T436/143333—Saccharide [e.g., DNA, etc.]
DE69032209T 1990-01-04 1990-12-19 In menschlichen kolorektalkarzinomen fehlendes gen Expired - Fee Related DE69032209T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US46098190A 1990-01-04 1990-01-04
PCT/US1990/007314 WO1991009964A1 (en) 1990-01-04 1990-12-19 Gene deleted in colorectal cancer of humans

Publications (2)

Publication Number Publication Date
DE69032209D1 true DE69032209D1 (de) 1998-05-07
DE69032209T2 DE69032209T2 (de) 1998-12-03

Family

ID=23830791

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69032209T Expired - Fee Related DE69032209T2 (de) 1990-01-04 1990-12-19 In menschlichen kolorektalkarzinomen fehlendes gen

Country Status (10)

Country Link
US (5) US5532108A (de)
EP (1) EP0507852B1 (de)
JP (1) JPH05508307A (de)
AT (1) ATE164629T1 (de)
AU (1) AU649431B2 (de)
CA (1) CA2073186C (de)
DE (1) DE69032209T2 (de)
DK (1) DK0507852T3 (de)
ES (1) ES2115611T3 (de)
WO (1) WO1991009964A1 (de)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9201929D0 (sv) * 1992-06-23 1992-06-23 Pharmacia Lkb Biotech Method and system for molecular-biological diagnostics
JP3151054B2 (ja) 1992-06-25 2001-04-03 協和醗酵工業株式会社 抗ｄｃｃ遺伝子産物モノクローナル抗体
WO1994020616A1 (en) * 1993-03-05 1994-09-15 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Colon mucosa gene having down-regulated expression in colon adenomas and adenocarcinomas
JPH09501045A (ja) * 1993-05-26 1997-02-04 ザ・ジョーンズ・ホプキンス・ユニバーシティ Ｄｃｃ遺伝子産物特異的抗体
US5709998A (en) * 1993-12-15 1998-01-20 The Johns Hopkins University Molecular diagnosis of familial adenomatous polyposis
CH686982A5 (fr) * 1993-12-16 1996-08-15 Maurice Stroun Méthode pour le diagnostic de cancers.
US5693473A (en) * 1994-08-12 1997-12-02 Myriad Genetics, Inc. Linked breast and ovarian cancer susceptibility gene
US5709999A (en) * 1994-08-12 1998-01-20 Myriad Genetics Inc. Linked breast and ovarian cancer susceptibility gene
US5753441A (en) * 1994-08-12 1998-05-19 Myriad Genetics, Inc. 170-linked breast and ovarian cancer susceptibility gene
ATE198623T1 (de) * 1994-08-12 2001-01-15 Myriad Genetics Inc Verfahren zum nachweis von prädisposition von ovarial- und brustkrebs
US5747282A (en) * 1994-08-12 1998-05-05 Myraid Genetics, Inc. 17Q-linked breast and ovarian cancer susceptibility gene
US5702886A (en) * 1994-10-05 1997-12-30 The Johns Hopkins University Chromosome I8Q loss and prognosis in colorectal cancer
US6743779B1 (en) 1994-11-29 2004-06-01 Imarx Pharmaceutical Corp. Methods for delivering compounds into a cell
US5891629A (en) * 1995-09-28 1999-04-06 Ambion, Inc. Compositions for improving RNase cleavage of base pair mismatches in double-stranded nucleic acids
GB9518156D0 (en) * 1995-09-06 1995-11-08 Medical Res Council Method of isolating cells
US5670325A (en) * 1996-08-14 1997-09-23 Exact Laboratories, Inc. Method for the detection of clonal populations of transformed cells in a genomically heterogeneous cellular sample
US5741650A (en) * 1996-01-30 1998-04-21 Exact Laboratories, Inc. Methods for detecting colon cancer from stool samples
EP1291657A3 (de) * 1996-01-30 2003-08-27 Exact Sciences Corporation Verfahren zum Nachweis von Kolonkrebs aus Stuhlproben
JP2001507207A (ja) * 1996-05-01 2001-06-05 イマアーレクス・フアーマシユーチカル・コーポレーシヨン 化合物を細胞に送達する方法
US5858665A (en) * 1996-07-25 1999-01-12 Navix, Inc. Homogeneous diagnostic assay method utilizing simultaneous target and signal amplification
US6203993B1 (en) 1996-08-14 2001-03-20 Exact Science Corp. Methods for the detection of nucleic acids
US6146828A (en) * 1996-08-14 2000-11-14 Exact Laboratories, Inc. Methods for detecting differences in RNA expression levels and uses therefor
US6020137A (en) * 1996-08-14 2000-02-01 Exact Laboratories, Inc. Methods for the detection of loss of heterozygosity
US5928870A (en) * 1997-06-16 1999-07-27 Exact Laboratories, Inc. Methods for the detection of loss of heterozygosity
US6100029A (en) * 1996-08-14 2000-08-08 Exact Laboratories, Inc. Methods for the detection of chromosomal aberrations
US6300077B1 (en) 1996-08-14 2001-10-09 Exact Sciences Corporation Methods for the detection of nucleic acids
US5830665A (en) * 1997-03-03 1998-11-03 Exact Laboratories, Inc. Contiguous genomic sequence scanning
US6268136B1 (en) 1997-06-16 2001-07-31 Exact Science Corporation Methods for stool sample preparation
US6406857B1 (en) 1997-06-16 2002-06-18 Exact Sciences Corporation Methods for stool sample preparation
US20020064792A1 (en) * 1997-11-13 2002-05-30 Lincoln Stephen E. Database for storage and analysis of full-length sequences
US6503718B2 (en) 1999-01-10 2003-01-07 Exact Sciences Corporation Methods for detecting mutations using primer extension for detecting disease
US6280947B1 (en) 1999-08-11 2001-08-28 Exact Sciences Corporation Methods for detecting nucleotide insertion or deletion using primer extension
DE60012688T2 (de) * 1999-01-14 2005-07-28 Ca*Tx, Inc. Immunoassays zum nachweis von krankheiten oder krankheitsanfälligkeitsmerkmalen
US7148016B1 (en) 1999-01-14 2006-12-12 Ca*Tx Inc. Immunoassays to detect diseases or disease susceptibility traits
CA2362251C (en) 1999-02-25 2008-06-17 Exact Sciences Corporation Methods for preserving dna integrity
AU767983B2 (en) * 1999-04-09 2003-11-27 Esoterix Genetic Laboratories, Llc Methods for detecting nucleic acids indicative of cancer
US6586177B1 (en) * 1999-09-08 2003-07-01 Exact Sciences Corporation Methods for disease detection
US6849403B1 (en) 1999-09-08 2005-02-01 Exact Sciences Corporation Apparatus and method for drug screening
JP2003516138A (ja) * 1999-12-07 2003-05-13 エグザクト サイエンシーズ コーポレイション 結腸上好気性消化新生物の検出
US6919174B1 (en) * 1999-12-07 2005-07-19 Exact Sciences Corporation Methods for disease detection
AU2001260116A1 (en) * 2000-03-14 2001-09-24 Bayer Aktiengesellschaft Human dcc-like proteins
US6492120B1 (en) 2000-11-02 2002-12-10 University Of Maryland Nucleic acid hybridization assay utilizing tricyclic target and signal amplification
US6428964B1 (en) 2001-03-15 2002-08-06 Exact Sciences Corporation Method for alteration detection
US20050130149A1 (en) * 2001-10-25 2005-06-16 Osborne Lucy R. Method for williams-beuren syndrome diagnosis
AU2003213107A1 (en) * 2002-02-15 2003-09-09 Exact Sciences Corporation Methods for analysis of molecular events
WO2004090547A2 (en) * 2003-04-04 2004-10-21 Protein Design Labs, Inc. Metastatic colorectal cancer signatures
US20040259101A1 (en) * 2003-06-20 2004-12-23 Shuber Anthony P. Methods for disease screening
JP2007512509A (ja) * 2003-11-05 2007-05-17 エグザクト サイエンシーズ コーポレイション 反復的親和性分離およびその使用
WO2005111244A2 (en) * 2004-05-10 2005-11-24 Exact Sciences Corporation Methods for detecting a mutant nucleic acid
WO2005113769A1 (en) * 2004-05-14 2005-12-01 Exact Sciences Corporation Method for stabilizing biological samples for nucleic acid analysis
WO2006026654A2 (en) 2004-08-27 2006-03-09 Exact Sciences Corporation Method for detecting a recombinant event
WO2006047787A2 (en) 2004-10-27 2006-05-04 Exact Sciences Corporation Method for monitoring disease progression or recurrence
DE602005009324D1 (de) 2005-04-06 2008-10-09 Maurice Stroun Methode zur Krebsdiagnose mittels Nachweis von DNA und RNA im Kreislauf
US9777314B2 (en) 2005-04-21 2017-10-03 Esoterix Genetic Laboratories, Llc Analysis of heterogeneous nucleic acid samples
JP2016513462A (ja) 2013-03-14 2016-05-16 アボツト・モレキユラー・インコーポレイテツド 細胞作製物及び細胞支持体、及びテラノーシスにおけるその使用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4831124A (en) * 1980-12-10 1989-05-16 Research Corporation Technologies Recombinant cDNA construction method and hybrid nucleotides useful in cloning
US5380645A (en) * 1989-03-16 1995-01-10 The Johns Hopkins University Generalized method for assessment of colorectal carcinoma
US5043272A (en) * 1989-04-27 1991-08-27 Life Technologies, Incorporated Amplification of nucleic acid sequences using oligonucleotides of random sequence as primers
JP3151054B2 (ja) * 1992-06-25 2001-04-03 協和醗酵工業株式会社 抗ｄｃｃ遺伝子産物モノクローナル抗体

Also Published As

Publication number Publication date
US5561223A (en) 1996-10-01
ATE164629T1 (de) 1998-04-15
ES2115611T3 (es) 1998-07-01
AU649431B2 (en) 1994-05-26
EP0507852A4 (en) 1993-04-28
WO1991009964A1 (en) 1991-07-11
US5650281A (en) 1997-07-22
EP0507852B1 (de) 1998-04-01
US5532108A (en) 1996-07-02
DE69032209T2 (de) 1998-12-03
DK0507852T3 (da) 1999-01-04
AU7158591A (en) 1991-07-24
JPH05508307A (ja) 1993-11-25
EP0507852A1 (de) 1992-10-14
US5874545A (en) 1999-02-23
US5602243A (en) 1997-02-11
CA2073186C (en) 2002-06-11
CA2073186A1 (en) 1991-07-05

Similar Documents

Publication Publication Date Title
DE69032209D1 (de) In menschlichen kolorektalkarzinomen fehlendes gen
EP0390323A3 (de) Nachweis des Ausfalls des Wildtyps des p53-Gens
ATE194660T1 (de) Veraendertes gen bei menschlichem colorektalem- krebs
AU1726199A (en) Metastatic cancer regulated gene
DE69133528D1 (de) Proteinkomplex p53/p90
ATE386804T1 (de) Gene mit veränderter expression in metastatischen brust- oder dickdarm- krebszellen
ATE130873T1 (de) Nachweis der expression von neu genen und produkten.
MA26557A1 (fr) Determination du caractere anormal de croissance cellulaire
AU6473598A (en) Method for determining the presence of mutated brca protein
EP0163304A3 (de) Menschliche monoklonale Antikörper gegen Zwischenfäden
WO1997022721A3 (en) Cancer detection probes
DK1135513T4 (da) Adenovirus-medieret genterapi
Okada et al. Metastasizing eccrine sweat gland carcinoma: report of a case
Tsung Localization of alpha-fetoprotein synthesis in malignancies other than hepatoma
IT8683362A0 (it) Procedimento e uso di un colorante naturale rosso ad alta intensita'derivato dalla coltura dei tessuti cellulari di carota.
DE68911305T2 (de) Das lungenwachstum stimulierende und hemmende faktoren für krebstumorzellen.
DE69839846D1 (de) Bestimmung der vorhandenen mengen an cyclin-abhängr bei krebspatienten
Vogelstein DCC probes, primers, and kits
SU635271A1 (ru) Детандер
SU588336A1 (ru) Породоразрушающа вставка
SU580302A1 (ru) Дисковое долото
SU606018A1 (ru) Подшипник скольжени
EP1985701A3 (de) In Brustkrebs differenziell exprimierte Gene
SU968440A1 (ru) Секци механизированной крепи
AU2003232724A1 (en) A novel biological cancer marker and methods for determining the cancerous or non-cancerous phenotype of cells

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee